Randomized Controlled Trial on Robotic Exoskeleton in Spinal Cord Injury: Clinical Outcomes and Cortical Plasticity

December 15, 2021 updated by: Azienda Usl di Bologna

Randomized Controlled Trial on Rehabilitation Training With a Robotic Anthropomorphic Exoskeleton in Patients With Motor Incomplete Spinal Cord Injury: Clinical Outcomes and Cortical Plasticity Indicators

The recent introduction of robotics for locomotor training in paraplegic patients, and in particular the use of anthropomorphic exoskeletons, has opened new frontiers in rehabilitation. Existing literature, though encouraging, is still scarce and studies demonstrating efficacy are highly heterogeneous and have a small sample size. Evidence is also needed about cortical plasticity after SCI, in conjunction with the use of innovative rehabilitation devices, through indicators like neurophysiological and neuroradiological markers, as the knowledge of such mechanisms is crucial to improve clinical outcomes. Cortical circuits controlling prosthetic devices are different from those controlling normal parts of the body and remodeling mechanisms following prosthetic use have been documented, but in conditions other than SCI.

The aims of this randomized controlled trial, with a 2-arm parallel-group design, are:

  1. to evaluate and quantify the efficacy of locomotor rehabilitation with a robotic anthropomorphic exoskeleton (EKSO-GT) in terms of clinical and functional outcomes, and the persistence of such efficacy;
  2. to investigate the presence and persistence of brain neuronal plasticity and cortical remodeling mechanisms underlying the robotic rehabilitation approach.

Fifty patients will be recruited and randomly assigned to 2 treatment arms. Both groups will follow a program of standard locomotor rehabilitation for 8 weeks. One group will also undergo an overground locomotor training with the EKSO-GT during the first 4 weeks.

Study Overview

Detailed Description

The increasing incidence of incomplete Spinal Cord Injury (SCI) has raised new rehabilitation challenges. Recovery of walking is one of the top priorities in SCI persons and growing efforts have been pursued aimed at identifying effective alternative techniques for improving gait performance.

Standard rehabilitation approach has been so far the most widely used, but the recent introduction of anthropomorphic exoskeletons may open new frontiers in the field. Anthropomorphic exoskeletons have been developed to assist SCI patients with mobility, but there is also a certain optimism that they may have potentialities to improve walking patterns of incomplete SCI persons after a rehabilitation period with such devices is terminated. So far, however, while different systematic reviews and meta-analyses have reported on the safety of the training with such exoskeletons, there are no significant Fiftystudies on its efficacy. Along with this, central mechanisms underlying the anatomical and functional changes induced by these approaches have never been investigated in SCI.

This longitudinal randomized controlled trial, with a 2-arm parallel group design, aims at evaluating the efficacy of the training with an anthropomorphic, robotized exoskeleton (EKSO-GT, by Ekso Bionics), as "add-on" to the standard locomotor rehabilitation, in improving walking performance, when compared to the standard locomotor rehabilitation alone, in a population of patients with non-acute motor incomplete SCI. Along with this and other clinical outcomes, neurophysiological and structural markers of Central Nervous System (CNS) plasticity will be explored, aimed at capturing mechanisms underlying how anthropomorphic exoskeletons affect CNS plasticity.

Fifty patients will be recruited in 3 Italian rehabilitation hospitals setting and assigned to 2 groups, with an allocation ratio of 1:1, through a block randomization approach. One group will perform a 4-week standard locomotor training (sLT) alone, while the other will perform a 4-week period sLT plus a training with the EKSO-GT (sLT + EX-T). Afterwards, both groups will undergo a further 4-week sLT alone.

Patients will be evaluated at several time points (always when the exoskeleton is not worn): clinical outcomes will be assessed by means of clinical examinations, standardized tests and validated scales; neurophysiological modulations will be evaluated by means of paired Motor and Sensory Evoked Potentials and a study of Electroencephalographic (EEG) slow waves oscillations and signal coherence during sleep; anatomical and structural cortical modifications will be studied with brain functional Magnetic Resonance Imaging (fMRI).

It is expected that the overground locomotor training with a new-generation exoskeleton, as "add-on" to standard locomotor training, can further improve clinical outcomes (especially walking performance) in the studied population, and that such clinical improvements are underlined by mechanisms modulating synaptic plasticity occurring also at the CNS level.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • BO
      • Bologna, BO, Italy, 40139
        • Recruiting
        • Azienda USL di Bologna, Istituto delle Scienze Neurologiche di Bologna (IRCCS ISNB)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 63 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • SCI due to traumatic or vascular etiology;
  • Incomplete motor SCI (C or D in ASIA Impairment Scale);
  • T1-L1 (included) neurological level;
  • 1-5 years since injury;
  • Functional gait ability (also with braces or orthoses);
  • Sufficient Range of Motion (ROM) of lower limbs joints to achieve a reciprocal gait pattern and allow transition from sitting to vertical position;
  • Stable clinical conditions;
  • Minimum height of 157 cm;
  • Maximum height of 188 cm;
  • Maximum weight of 100 Kg;
  • Maximum intertrochanteric distance of 46 cm;
  • Cognitive integrity and full collaboration of the subject.
  • Specific research informed consent signed.

Exclusion Criteria:

  • Intensive walking rehabilitation training undergone in the last 3 months;
  • Previous use of a robotic exoskeleton;
  • Instability or major deformity of the spine;
  • Lower limbs joints instability;
  • Indication to spinal orthosis;
  • Uncontrolled spasticity (score > 3 of the Modified Ashworth Scale) in the majority of the muscle groups of the lower limbs;
  • History of traumatic brain injury;
  • Recent significant bone fractures, traumatic and/or pathological for the required training;
  • Presence of neurogenic paraosteoarthropathies (POAN) at the onset or phlogistic phase;
  • Discrepancy in femurs length (> 1.3 cm) and legs length (> 1.9 cm);
  • Symptomatic orthostatic hypotension;
  • Severe and recurrent uncontrolled autonomic dysreflexia;
  • Cardiopulmonary comorbidities limiting physical effort;
  • Skin lesions that can interfere with the study rehabilitation trainings;
  • Documented psychiatric pathology;
  • Contraindications to fMRI and polygraphic EEG execution;
  • Contraindications to TMS;
  • Ongoing pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: sLT
Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
Experimental: sLT + EX-T
Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in walking performance
Time Frame: Baseline (initial visit post-randomization); week 4
10-meter walk test
Baseline (initial visit post-randomization); week 4

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in walking performance
Time Frame: Baseline (initial visit post-randomization); week 8
10-meter walk test
Baseline (initial visit post-randomization); week 8
Change in walking endurance
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
6-minute walk test
Baseline (initial visit post-randomization); week 4; week 8
Change in functional walking capacity
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Walking Index for Spinal Cord Injury II (WISCI II)
Baseline (initial visit post-randomization); week 4; week 8
Change in spasticity
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Modified Ashworth Scale
Baseline (initial visit post-randomization); week 4; week 8
Change in pain
Time Frame: Baseline (initial visit post-randomization); every day, twice a day for the whole study period; overall appraisal at week 4 and week 8
Numeric Rating Scale (NRS)
Baseline (initial visit post-randomization); every day, twice a day for the whole study period; overall appraisal at week 4 and week 8
Change in mood state
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Profile of Mood States questionnaire (POMS)
Baseline (initial visit post-randomization); week 4; week 8
Change in lower limbs muscle strength
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Lower Extremity Motor Score (LEMS) of the American Spinal Injury Association (ASIA) Impairment Scale
Baseline (initial visit post-randomization); week 4; week 8
Change in lower limbs muscle activation pattern
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Gait Dynamic Electromyography (DEMG)
Baseline (initial visit post-randomization); week 4; week 8
Change in entity of neuronal plasticity and cortical remodelling of motor cortical areas
Time Frame: Baseline (initial visit post-randomization); after the first locomotor training session; week 4; week 8
Change in short-term intracortical inhibition through Motor Evoked Potentials (PEMs) elicited by Transcranial Magnetic Stimulation (TMS)
Baseline (initial visit post-randomization); after the first locomotor training session; week 4; week 8
Change in entity of neuronal plasticity and cortical remodelling of sensory cortical areas
Time Frame: Baseline (initial visit post-randomization); after the first locomotor training session; week 4; week 8
Somatosensory Evoked Potentials (SSEs) at cortical level
Baseline (initial visit post-randomization); after the first locomotor training session; week 4; week 8
Change in synaptic potentiation (neuroprosthetic learning)
Time Frame: Baseline (initial visit post-randomization); after the first locomotor training session; week 4
Analysis of slow-wave oscillations with Electroencephalographic (EEG) polysomnography (PSG)
Baseline (initial visit post-randomization); after the first locomotor training session; week 4
Change in synaptic potentiation (neuroprosthetic learning)
Time Frame: Baseline (initial visit post-randomization); after the first locomotor training session; week 4
Analysis of EEG coherence signal
Baseline (initial visit post-randomization); after the first locomotor training session; week 4
Change in brain anatomy and cortical structure
Time Frame: Baseline (initial visit post-randomization); week 4; week 8
Functional Magnetic Resonance Imaging (fMRI)
Baseline (initial visit post-randomization); week 4; week 8
Evaluation of patient's satisfaction for the training received
Time Frame: Week 4
Ad-hoc questionnaire
Week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2020

Primary Completion (Anticipated)

November 1, 2022

Study Completion (Anticipated)

November 1, 2022

Study Registration Dates

First Submitted

February 16, 2018

First Submitted That Met QC Criteria

February 16, 2018

First Posted (Actual)

February 23, 2018

Study Record Updates

Last Update Posted (Actual)

December 16, 2021

Last Update Submitted That Met QC Criteria

December 15, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Cord Injuries

Clinical Trials on Standard neurorehabilitation locomotor training

3
Subscribe